These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

353 related items for PubMed ID: 9768527

  • 1. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome.
    Delvaux M, Louvel D, Mamet JP, Campos-Oriola R, Frexinos J.
    Aliment Pharmacol Ther; 1998 Sep; 12(9):849-55. PubMed ID: 9768527
    [Abstract] [Full Text] [Related]

  • 2. Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome.
    Thumshirn M, Coulie B, Camilleri M, Zinsmeister AR, Burton DD, Van Dyke C.
    Aliment Pharmacol Ther; 2000 Jul; 14(7):869-78. PubMed ID: 10886042
    [Abstract] [Full Text] [Related]

  • 3. Lipid-induced colonic hypersensitivity in irritable bowel syndrome: the role of 5-HT3 receptors.
    Simrén M, Simms L, D'Souza D, Abrahamsson H, Björnsson ES.
    Aliment Pharmacol Ther; 2003 Jan; 17(2):279-87. PubMed ID: 12534414
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome.
    Bardhan KD, Bodemar G, Geldof H, Schütz E, Heath A, Mills JG, Jacques LA.
    Aliment Pharmacol Ther; 2000 Jan; 14(1):23-34. PubMed ID: 10632642
    [Abstract] [Full Text] [Related]

  • 8. Review article: clinical pharmacology of alosetron.
    Gunput MD.
    Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():70-6. PubMed ID: 10429744
    [Abstract] [Full Text] [Related]

  • 9. The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients.
    Mayer EA, Berman S, Derbyshire SW, Suyenobu B, Chang L, Fitzgerald L, Mandelkern M, Hamm L, Vogt B, Naliboff BD.
    Aliment Pharmacol Ther; 2002 Jul; 16(7):1357-66. PubMed ID: 12144587
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients.
    Jones RH, Holtmann G, Rodrigo L, Ehsanullah RS, Crompton PM, Jacques LA, Mills JG.
    Aliment Pharmacol Ther; 1999 Nov; 13(11):1419-27. PubMed ID: 10571597
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Oxytocin increases thresholds of colonic visceral perception in patients with irritable bowel syndrome.
    Louvel D, Delvaux M, Felez A, Fioramonti J, Bueno L, Lazorthes Y, Frexinos J.
    Gut; 1996 Nov; 39(5):741-7. PubMed ID: 9014776
    [Abstract] [Full Text] [Related]

  • 15. Alosetron.
    Balfour JA, Goa KL, Perry CM.
    Drugs; 2000 Mar; 59(3):511-8; discussion 519-20. PubMed ID: 10776833
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.
    Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW.
    Lancet; 2000 Mar 25; 355(9209):1035-40. PubMed ID: 10744088
    [Abstract] [Full Text] [Related]

  • 17. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.
    Camilleri M, Chey WY, Mayer EA, Northcutt AR, Heath A, Dukes GE, McSorley D, Mangel AM.
    Arch Intern Med; 2001 Jul 23; 161(14):1733-40. PubMed ID: 11485506
    [Abstract] [Full Text] [Related]

  • 18. Alosetron does not affect the visceral perception of gastric distension in healthy subjects.
    Zerbib F, Bruley des Varannes S, Oriola RC, McDonald J, Isal JP, Galmiche JP.
    Aliment Pharmacol Ther; 1994 Aug 23; 8(4):403-7. PubMed ID: 7986965
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.